|
| Status |
Public on Aug 22, 2022 |
| Title |
RNA data of baseline and ERY974-treated tumour samples for various xenograft tumors (PC10, NCI-H446, MKN45, and MKN74). |
| Organisms |
Homo sapiens; Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
GPC3 expression is one of the important predictive marker of ERY974. However, we found that efficacy of ERY974 is sometimes different in tumors with the similar GPC3 expression.
To identify a predictive biomrker of ERY974, we compared baseline RNA expression of tumors in which ERY974 shows moderate efficacy, and/or achives the regression with similar GPC3 expression.
|
| |
|
| Overall design |
Comparative gene expression profiling analysis of RNA-seq data for tumors of PC10 (ERY974 shows regression/GPC3 high), NCI-H446 (ERY974 shows moderate efficacy/GPC3 high), MKN74 (ERY974 shows regression/GPC3 low), and MKN45(ERY974 shows moderate efficacy/GPC3 low).
|
| |
|
| Contributor(s) |
Sano Y, Nishito Y, Azuma Y, Kinoshita Y, Tsunenari T, Ishiguro T |
| Citation(s) |
36071036 |
| |
| Submission date |
Aug 17, 2022 |
| Last update date |
Nov 21, 2022 |
| Contact name |
YUJI SANO |
| E-mail(s) |
sanoyuj@chugai-pharm.co.jp
|
| Phone |
+810467476241
|
| Organization name |
Chugai Pharmaceutical Co., Ltd
|
| Street address |
200
|
| City |
Kajiwara |
| State/province |
Kamakura |
| ZIP/Postal code |
247-8530 |
| Country |
Japan |
| |
|
| Platforms (1) |
| GPL22245 |
Illumina HiSeq 2500 (Homo sapiens; Mus musculus) |
|
| Samples (24)
|
|
| Relations |
| BioProject |
PRJNA870580 |
Less...
More...